Skip to main content

Table 3 Comparison of adverse events by the best objective response on target lesions

From: The best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study

Adverse events All grades (%) Grades 3/4 (%)
All cases (n = 50) CR/PR (n = 12) SD (n = 22) PD (n = 6) NE (n = 10) All cases (n = 50) CR/PR (n = 12) SD (n = 22) PD (n = 6) NE (n = 10)
Any 100 100 100 100 100 30 25 27 50 30
Hematologic
Anemia 58 58 54 67 60 4 0 0 17 10
Neutorophils decreased 44 50 46 67 20 6 0 5 33 0
Lymphocyte decreased 36 42 36 50 20 6 8 5 0 10
Platelet decreased 58 67 50 83 50 24 17 27 50 10
Creatinine increased 38 33 41 33 40 0
Non-hematologic
Hypertension* 56 84 59 33 30 2 0 5 0 0
Hypothyroidism* 46 42 59 33 30 0
Fatigue 36 33 32 50 40 0
Diarrhea 30 33 36 0 30 0
Mucositis oral 28 17 46 17 10 0
Hand-foot syndrome 20 25 27 17 0 0
Fever up 18 25 9 33 20 0
Hemorrhage 16 8 23 17 10 0
Heart failure 4 8 5 0 0 0
  1. All the statistical analysis is performed with Fisher’s exact test, * P < 0.05
  2. CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluable